New paper: AI-driven Screening for Cardiac Amyloidosis using Scintigaphy Imaging
New paper in The Lancet Digital Health on the Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence in a retrospective, international, multicentre, cross-tracer development and validation studyAI-driven Screening for Cardiac Amyloidosis using Scintigaphy Imaging
New paper in The Lancet Digital Health: Cardiac amyloidosis is a severe disease in which misfolded proteins accumulate in the heart muscle, causing heart failure and death. Timely diagnosis is vital to initiate treatment before irreversible damage occurs. In this international study, a deep learning system for the screening of cardiac amyloidosis among more than 16,000 patients undergoing scintigraphy imaging was developed and validated in nine centers. The results indicated high diagnostic accuracy, removed inter-rater variability, and offered prognostic value, suggesting the possibility for clinical implementation to assist in the detection of cardiac amyloidosis.
Spielvogel, Clemens P., et al. Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study. The Lancet Digital Health, 2024, 6. Jg., Nr. 4, S. e251-e260